Treatment of Kawasaki Disease with Coronary Artery Z Score ≥2.5 (LAD or RCA) or Age Under 6 Months
Certain presentations of acute Kawasaki disease (KD) carry a higher risk of coronary artery involvement and require a structured initial treatment approach that goes beyond standard management. This protocol addresses two defined high-risk features identified at the time of initial evaluation.
Coronary artery Z score ≥2.5 for the left anterior descending (LAD) or right coronary artery (RCA) on initial echocardiography, or patient age under 6 months. A Z score of 2.5 or above is considered to represent a true aneurysm, distinguishing this population from lower-risk presentations and requiring a more intensive initial regimen.
Initial Treatment Approach
Treatment in this high-risk presentation centers on intravenous immunoglobulin (IVIG) combined with aspirin. Because of the elevated risk profile, adjunctive immunomodulatory therapy is incorporated alongside IVIG — the specific agent and regimen depend on the full clinical picture and are detailed in the structured protocol.
References
DOI: 10.1002/art.42041
- For this recommendation, the Voting Panel defined high-risk features as a Z score of ≥2.5 for the left anterior descending or right coronary artery at the time of the initial echocardiography and age <6 months.
- This definition uses the Z score of 2.5 instead of 2.0, since a score of 2.5 is defined as representing a true aneurysm.
- For patients with acute KD who are at high risk of IVIG resistance or developing coronary artery aneurysms, use of IVIG with adjunctive glucocorticoids as initial therapy is conditionally recommended over treatment with IVIG alone.
- For patients with acute KD, using aspirin is strongly recommended over no aspirin.
- IVIG has been established as the standard-of-care treatment for KD for the last 4 decades due to the significant reduction in the rate of coronary artery aneurysms as well as a reduction in the duration of fever and other symptoms associated with its use.